Archiv der Kategorie ‘Healthcare‘

8×8 (EGHT) Upgrade from Market Perform to Outperform – Analyst rating from Northland Capital

Friday, den 1. March 2013

8×8 (EGHT) Downgrade from Outperform to Market Perform – Analyst rating from Northland Securities

Friday, den 25. January 2013

8×8 (EGHT) Upgrade from Market Perform to Outperform – Analyst rating from Northland Securities

Tuesday, den 9. August 2011

8×8 ( EGHT ) Upgrade from Market Perform to Outperform – Analyst rating from Northland Securities

Tuesday, den 9. August 2011

RDY – Dr. Reddys Announces the Launch of Gemcitabine for Injection

Wednesday, den 27. July 2011

Dr. Reddy’s Q1 FY12 Financial Results

Wednesday, den 20. July 2011

Key Highlights Consolidated revenues are at Rs. 19.7 billion ($444 million) in Q1 FY12 versus Rs. 16.8 billion ($377 million) in Q1 FY11, year-on-year growth of 18%. Revenues from Global Generics for Q1 FY12 are at Rs. 14.4 billion ($323 million). Year-on-year growth of 21% mainly driven by North America generics and Russia. Revenues from […]

Dr. Reddy’s Laboratories

Wednesday, den 1. June 2011

Dr. Reddy’s Laboratories is an integrated pharmaceutical company and operates in business segments such as global generics, active ingredients and proprietary products. Dr Reddy’s March quarter results were higher-than-estimated with revenue growing 22.8% year-over-year, driven by robust growth of 67.6% in U.S. generics and 25.7% in Russia and CIS. The launch of generic fexofenadine pseudoephedrine […]

Dr Reddy’s says U.S. court clears generic Allegra sale

Wednesday, den 2. February 2011

“This is a positive for the company. Since Dr Reddy’s is the only player for this product, it should be able to do decent sales,” Sarabjit Kour Nangra, vice president of research and who tracks the sector at Angel Broking said. Dr. Reddy’s Laboratories announced today that on Friday, 28 January 2011, the U.S. District […]

Dr Reddy’s Laboratories will start to see the benefits from its tie-up with GlaxoSmithKline in two or three years

Wednesday, den 2. February 2011

“Overall, it is a good relationship that is working well and going as predicted, but the financial impact is going to be seen only two to three years from now,” he told Reuters on the sidelines of the annual meeting of the World Economic Forum. “It takes time to develop the products and register them […]

8×8 (EGHT) Downgrade from Outperform to Market Perform – Analyst rating from Northland Securities

Thursday, den 27. January 2011

8×8 ( EGHT ) Downgrade from Outperform to Market Perform – Analyst rating from Northland Securities

Thursday, den 27. January 2011

Dr. Reddy’s Laboratories Ltd. (RDY) Q3 2011 Earnings Call

Wednesday, den 26. January 2011

The financial highlights are as follows. Consolidated revenues for the quarter are at $424 million and represent a year-on-year growth of 10% and a sequential growth of 2%. Revenues from our Global Generics business stand at $303 million for the quarter, representing a year-on-year growth of 16%. Revenues from the Pharmaceutical Services and Active Ingredients […]

Dr Reddy’s profit hurt by German unit, shares fall

Wednesday, den 26. January 2011

Dr Reddy’s Laboratories, India’s No. 2 drugmaker, swung to a profit in the third quarter but missed analysts’ estimates as sales at its German unit plunged. Sales in Europe, one of Dr Reddy’s largest markets, fell 18 percent, driven by a 33-percent drop in Germany, as its German unit Betapharm struggled with pricing pressure amid […]

Biosimilars – The Next Generic Honeypot

Tuesday, den 14. September 2010

Generic drugs are certainly a significant part of the landscape in the healthcare world. Not only do they save healthcare consumers (and their insurance companies) millions of dollars a year, but they are a thriving industry in their own right. Companies like India’s Dr. Reddy’s Laboratories (NYSE:RDY) and its nearly ten-fold larger rival Teva Pharmaceuticals […]

8×8 (EGHT) Initial Recommendation – Outperform – Analyst rating from Northland Securities

Monday, den 22. March 2010

8×8 ( EGHT ) Initial Recommendation Outperform – Analyst rating from Northland Securities

Monday, den 22. March 2010

Dr Reddy’s forecasts low single digit revenue growth in FY10

Wednesday, den 20. January 2010

Chief Executive G.V. Prasad said the company expected to post a “low single digit” revenue growth in the fiscal year that ends in March, down from its previous forecast of a 10-percent growth over the previous year. “Our German business has contracted beyond our expectations and there is a little bit of slowdown in the […]

Dr Reddy’s posts $113 mln net loss in Q3

Wednesday, den 20. January 2010

Indian drug maker Dr Reddy’s Laboratories Ltd posted a 5.2 billion rupees consolidated loss ($113 million) in the December quarter, compared with a profit of 2.4 billion rupees in the year-ago period, missing forecasts. Dr Reddy’s, India’s second-biggest drug maker by sales, said in September it had voluntarily recalled four products from its key U.S. […]

Dr. Reddy’s (RDY) Downgrade from Hold to Sell – Analyst rating from Deutsche Bank

Tuesday, den 19. January 2010

Dr. Reddy’s downgraded by Deutsche Bank

Tuesday, den 19. January 2010

Transgene Biotek Sells Obesity Drug Technology License To Dr Reddy’s

Thursday, den 7. January 2010

Transgene Biotek Ltd. said Thursday it has sold the license for the manufacturing process of obesity drug orlistat to Dr. Reddy’s Laboratories Ltd.

Analyst rating from Credit Suisse – Upgrade Dr. Reddy’s ( RDY ) from Neutral to Outperform

Monday, den 26. October 2009

Merck startet Phase-III-Studie mit Safinamid

Wednesday, den 28. November 2007

Merck Serono, eine Sparte der Merck KGaA, und ihr Partner Newron Pharmaceuticals S.p.A. haben eine klinische Phase-III-Studie mit Safinamid gestartet. Wie der im DAX30 notierte Pharmakonzern am Mittwoch erklärte, wird Safinamid dabei als Begleittherapie bei idiopathischer Parkinson-Erkrankung im Frühstadium getestet. Die Studie wird die Sicherheit und Wirksamkeit von zwei Dosierungen von Safinamid (50 mg und […]

Human Genome Sciences outperform

Wednesday, den 19. September 2007

Sanford C. Bernstein & Co stufen die Aktie von Human Genome Sciences in ihrer Ersteinschätzung mit “outperform” ein. Das Kursziel wird bei 13 US-Dollar gesehen.

Human Genome erhält Meilensteinzahlung von Novartis

Friday, den 7. September 2007

Human Genome Sciences Inc. wird vom schweizerischen Pharmakonzern Novartis AG eine Meilensteinzahlung in zweistelliger Millionenhöhe erhalten.

Neue Spekulationen um Bayer und Novartis

Wednesday, den 22. August 2007

Um Bayer AG ranken sich Übernahmespekulationen. Am Parkett wird darauf spekuliert, der Schweizer Pharmariese Novartis AG , der weltweit sechstgrößte Pharmakonzern und die Nummer vier in Europa, könnte ein Angebot für das Leverkusener Unternehmen vorlegen.

Human Genome verringert Verlust im zweiten Quartal

Wednesday, den 1. August 2007

Human Genome Sciences Inc. konnte den Verlust im zweiten Quartal deutlich reduzieren.Wie der Konzern am Mittwoch erklärte,

weekly winner – ENCY + 21,3%

Sunday, den 22. July 2007

Genentech posts 41% rise in profit, lifts full-year EPS view

Wednesday, den 11. July 2007

Genentech Inc. after Wednesday’s closing bell said it made $747 million, or 70 cents a share, in the second quarter, compared with $531 million, or 49 cents a share, in the same quarter last year.

Human Genome Sciences – Downgrade

Tuesday, den 26. June 2007

Lehman Brothers — 26.06.07 —- HGSI — downgrade von overweight auf equal weight — Kursziel gesenkt von 15 $ auf 10 $

Monsanto schliesst mit Bayer langfristige Vereinbarung

Thursday, den 21. June 2007

Monsanto schliesst mit Bayer CropScience langfristige Geschäfts- und Lizenzvereinbarung.

BASF overweight

Wednesday, den 20. June 2007

18.06.07 – Morgan Stanley – BASF overweight – price target 100 USD

Mylan Laboratories übernimmt Generikageschäft von Merck

Thursday, den 17. May 2007

Mylan wird man das Generikageschäft des deutschen Pharmakonzerns Merck für 4,9 Mrd. Euro übernehmen. Die Transaktion soll im zweiten Halbjahr 2007 abgeschlossen werden